Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...
While Both iStent and iStent inject Showed Significant IOP and Medication Reduction in Combo-Cataract Procedures at 1 Year Postoperative, iStent inject Achieved Greater Absolute IOP Declines with 93% ...
Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure for Advanced Glaucoma The iStent infinite is designed ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and ...
Glaucoma is a disease with no cure; left untreated, it can result in partial or complete loss of vision over time. It is not only the leading cause of blindness among African Americans and Hispanics ...
The iStent inject is designed to deploy two stents into separate trabecular meshwork locations and is being evaluated for IOP reduction. The company is also pursuing FDA approval of a third MIGS ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results